BFM
TERN

Boothbay Fund Management’s Terns Pharmaceuticals TERN Stock Holding History

Boothbay Fund Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.6M Buy
486,170
+39,162
+9% +$1.61M 0.33% 25
2025
Q4 		$18.1M Buy
447,008
+268,133
+150% +$6.2M 0.27% 54
2025
Q3 		$1.34M Buy
178,875
+122,411
+217% +$782K 0.02% 718
2025
Q2 		$211K Sell
56,464
-70,366
-55% -$220K ﹤0.01% 1230
2025
Q1 		$350K Hold
126,830
– – 0.01% 997
2024
Q4 		$703K Sell
126,830
-6
-0% -$41 0.02% 753
2024
Q3 		$1.06M Sell
126,836
-39,804
-24% -$327K 0.02% 733
2024
Q2 		$1.13M Buy
166,640
+151,208
+980% +$916K 0.03% 674
2024
Q1 		$101K Sell
15,432
-10,934
-41% -$71.4K ﹤0.01% 1417
2023
Q4 		$171K Hold
26,366
– – ﹤0.01% 1358
2023
Q3 		$133K Sell
26,366
-24,374
-48% -$155K ﹤0.01% 1509
2023
Q2 		$444K Sell
50,740
-76,812
-60% -$895K 0.01% 1160
2023
Q1 		$1.51M Buy
127,552
+1,670
+1% +$16K 0.03% 808
2022
Q4 		$1.28M Sell
125,882
-9,837
-7% -$65.5K 0.03% 793
2022
Q3 		$799K Buy
135,719
+29,007
+27% +$108K 0.02% 989
2022
Q2 		$265K Buy
+106,712
New +$213K 0.01% 1550

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Boothbay Fund Management's TERN Position: Q1 2026 in Review

Boothbay Fund Management increased its Terns Pharmaceuticals (TERN) stake by 8.8% in Q1 2026, buying an estimated $1.61M and bringing the position to 486,170 shares worth $25.6M. The position accounts for 0.33% of the portfolio, ranked #25.

Boothbay Fund Management first reported a position in TERN in Q2 2022 and has held it in 16 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Boothbay Fund Management held 486,170 shares of Terns Pharmaceuticals worth $25.6M as of Q1 2026.
  • Boothbay Fund Management bought 39,162 Terns Pharmaceuticals shares in Q1 2026, an estimated $1.61M.
  • Terns Pharmaceuticals made up 0.33% of Boothbay Fund Management's portfolio in Q1 2026, its #25 holding.
  • Boothbay Fund Management first reported a position in Terns Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.